Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
Celgene
Uwe Platzbecker; Matteo Giovanni Della Porta; Valeria Santini; Amer M Zeidan; Rami S Komrokji; Jake Shortt; David Valcarcel; Anna Jonasova; Sophie Dimicoli-Salazar; Ing Soo Tiong; Chien-Chin Lin; Jiahui Li; Jennie Zhang; Ana Carolina Giuseppi; Sandra Kreitz; Veronika Pozharskaya; Karen L Keeperman; Shelonitda Rose; Jeevan K Shetty; Sheida Hayati; Sadanand Vodala; Thomas Prebet; Andrius Degulys; Stefania Paolini; Thomas Cluzeau; Pierre Fenaux; Guillermo Garcia-Manero